 Single-Molecule, Real-Time (SMRT) DNA sequencing technology
Pacific Biosciences was funded in 2004 with the goal of developing Single-Molecule, Real-Time (SMRT) DNA sequencing technology. This technology enables, for the first time, the observation of natural DNA synthesis by a DNA polymerase as it occurs. Our approach is based on eavesdropping on a single DNA polymerase molecule working in a continuous, processive manner. Distinguished by its long reads, short run times, and high quality sequence data with less effort and cost, SMRT DNA sequencing promises to be a transformative technology that will enable a new paradigm in genomic analysis.
PacBio's SMRT technology is built upon two key innovations that overcome major challenges facing the field of DNA sequencing:
The SMRT chip, which enables observation of individual fluorophores against a dense background of labeled nucleotides by maintaining a high signal-to-noise ratio, and
Phospholinked nucleotides, which produce a completely natural DNA strand through fast, accurate, and processive DNA synthesis ...
|
|
Licor - Why Infra-Red Fluorescence
Near Infrared Fluorescent Approaches to Cell-Based Assays and Small Animal Imaging - Dr. Amy Schutz-Geschwender - May 1, 2007
Presented at Experimental Biology, May 1, 2007
...
|
|
 Introduction to Empire Genomics
The true story behind a revolutionary genomics firm. Empire Genomics, founded from the research of Dr. Norma Nowak, and driven by the desire to discover cures and better diagnostic tools.
Empire Genomics was created in 2006 from research started at the prestigious Roswell Park Cancer Institute in Buffalo, New York. The laboratory has a strong track record in the development of high throughput technologies to enable genome-wide analyses aimed at determining the underlying mechanisms for diseases. Having played a fundamental role in the Human Genome Project and created the foundational Bacterial Artificial Chromosomes which served as the basis for sequencing the genome, Empire Genomics developed significant expertise in genomic research. It is from this strong experiential base that we bring our capabilities, tools and techniques to support the research, clinical and drug discovery global community.
Empire Genomics - Company Profile on BioPortfolio's Biocorporate Database...
|
|
|
|
|
|
“How can I improve my practice?â€
vs. market-based prescribing; cost-effective prescribing; strategies to improve interaction with representatives; critical evaluation techniques of...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 Caliper Life Sciences - LabChip 3000
The LabChip 3000 is Calipers flagship enzymatic drug discovery system utilizing microfluidic technology for in vitro experiments.
The LabChip 3000 drug discovery system miniaturizes, integrates and automates enzymatic and cell-based assays. LabChip assays are separations-based, so the quality of results exceeds what is achievable in homogenous, well-based assays. High Z' values, few false positives, few false negatives and analytical quality reproducibility are the reasons cited for the increasing reliance on the LabChip 3000. No other screening system identifies weak enzyme inhibitors as reproducibly as the LabChip 3000.
Currently, 75% of the top 15 pharmaceutical companies are actively using Caliper systems as key tools in their screening efforts. Companies like Novartis, Johnson & Johnson, Sanofi-Aventis, Merck, Schering-Plough, Amgen, Lilly, Wyeth, and others are discovering the path to more productive screens. The most cited reason for using the Caliper system? Data quality. The number one application on the LabChip 3000 is kinase profiling, due to the high caliber of information that can be gained and the remarkably quick assay development time.
A variety of enzymatic assays can be performed on a single LabChip 3000 instrument. The assay menu for the LabChip 3000 includes:.
Serine/Threonine Kinases
Tyrosine Kinases
Phosphatases
Proteases
Lipid-modifying Enzymes
G-protein coupled receptors (GPCRs)
For more information visit: http://www.caliperls.com/products/labchip-systems/labchip3000.htm...
|
|
Biotechnology Expert; Graham Brookes, Agricultural Economist
Graham Brookes, an agricultural economist and director of UK-based PG Economics, discusses the magnitude of the economic and environmental benefits of biotechnology in agriculture since 1996 -- specifically citing a reduction in pesticide applications of 172,000 metric tons across four main biotech crops, an increase in global farm income of US$28 billion, and a reduction in greenhouse gases of 10 million metric tons....
|
|
Coblation® — A Powerful, Plasma-Based Technology
Learn about the plasma physics behind ArthroCare’s Coblation technology and how Coblation-based medical devices differ from traditional electrosurgical instruments. Also, hear expert commentary from Dr. Ian Brown — the founder of the plasma applications group at Lawrence Berkeley National Laboratory — who is currently involved in a collaborative research project with two leading Russian research institutes focused on new Coblation applications....
|
|
